Traders Stock tips

One New Stock Market Pick Each Week
To Build Your Winning Stock Trading Profits

Swing Trading Stocks

Your Ad Here

STW Biotech Stock
Reports & Analysis
BCRX    EP 4.74
CXM        EP .42
BDSI      EP 2.30
PPHM    EP 1.63
OREX     EP 4.14
ACTC      EP.073
TTNP     EP 1.03
SIGA      EP 6.67
XOMA     EP .46
GNBT       EP .36

Stock Trade of the Day

- Will run to $23+ on
BARDA Contract-Buy 5-16-11

This Weeks Stock Pick - Swing Trading Tip

6-15-2010 Stock Recommendation XOMA - Strong Buy

The STW Biotech penny stock swing trading recommendation for the week ending 6-18-2010 is XOMA. The company received good but expected news today that they will be given a 90 day extension to meet NASDAQ guidelines for continued listing.  While this was priced in we believe that this action will be a turning point in share price which has now passed resistance and the pivot point at .46 per share of XOMA stock.

 There has been an ongoing string of good news on the technology of the 2 lead drug candidates for eventual FDA approval for XOMA. Details are below on xoma 052 which is in phase 2 trials and shows promising results as a miracle anti-inflammatory that will become a key medicine for people with diabetes and coronary disease as will as many other inflammatory diseases, some of these other uses will be discussed on a conference call, Thursday 6-17. In addition XOMA has many drugs in varying stages of pre IND development coming out of the pipeline in the near future and they are one of the few developmental biotech companies that actually earn income from their many pharma research and production partnerships with major pharmaceutical companies. It is the belief of STW that in the mid term XOMA is a take over target in the future.

Or recommendation this week is for a swing trade with and entry point of between .44 and .48 looking for a swing into the .60+ range over the next 6 weeks for a 30% to 50% profit on the trade.

We are long XOMA.

June 15, 2010, 8:02 a.m. EDT ·
XOMA's Request for Continued Listing

BERKELEY, Calif., Jun 15, 2010 (GlobeNewswire via COMTEX) -- XOMA Ltd. /quotes/comstock/15*!xoma/quotes/nls/xoma (XOMA 0.46, +0.01, +2.33%) , a leader in the discovery and development of therapeutic antibodies, today announced that a NASDAQ Listing Qualifications Panel (the "Panel") has granted the company's request for an extension of time, as permitted under NASDAQ's Listing Rules, to comply with the $1.00 per share minimum bid price requirement for continued listing. In accordance with the Panel's decision, on or before September 13, 2010, the company must evidence a closing bid price of $1.00 or more for a minimum of ten consecutive trading days or its common shares will be subject to delisting from The NASDAQ Global Market. Under NASDAQ's rules, this date represents the maximum length of time that a Panel may grant to regain compliance.

The determination follows the company's hearing before the Panel on May 6, 2010, at which the Panel considered the company's plan to regain compliance with the minimum bid price requirement, including seeking shareholder approval of a potential reverse stock split at its 2010 annual general meeting of shareholders on July 21, 2010. The company is working diligently to satisfy the terms of the Panel's decision.

About XOMA

XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. The company's proprietary product pipeline includes:

·                            XOMA 052, an anti-IL-1 beta antibody in Phase 2 clinical development for Type 2 diabetes, Type 1 diabetes and cardiovascular disease, with potential for the treatment of a wide range of inflammatory conditions.

·                            XOMA 3AB, an antibody candidate in pre-IND studies to neutralize the botulinum toxin, among the most deadly potential bioterror threats, under development through funding provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (Contract # HHSN266200600008C).

·          A preclinical pipeline with candidates in development for several diseases.

In addition to its proprietary pipeline, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering Corporation, a subsidiary of Merck & Co., Inc. and Takeda Pharmaceutical Company Limited.

XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS® (ranibizumab injection) for wet age-related macular degeneration and CIMZIA® (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.

The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.

XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 215 employees at its Berkeley, California location. For more information, please visit


Bollinger Bands

XOMA is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.


XOMA's MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.


The Stochastic Oscillator is registering a strong bullish signal as the %K has crossed above the %D and the oscillator recently moved above the critical value of 20 and is no longer oversold.

Ultimate Oscillator

According to the Ultimate Oscillator which is currently at 28.12%, below the critical value of 30, XOMA may be oversold. While this does not necessarily mean that the stock will rally, it does suggest that selling pressure may not be sustainable at the current level.

STW Biotech
Stock Watch List



Sign Up
For STW Email
Trading Alerts



| HomeThis Weeks Tip | About Our Picks | Market research | Privacy-Terms |©2006-2010      Contact:      Website Managed by TRM Daytona Beach, Florida

This website is for information purposes only. All stock market investments have risk and may increase or decline. The management of this site is not responsible for any profit or loss you experience, do your own due diligence an any company before investing, our stock tips are only a starting point, you are ultimately responsible for your own investment decisions.